Moxifloxacin

Tuberculosis

Volumn 88, Issue 2, 2008, Pages 127-131

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ACTIMAX; ANTACID AGENT; ANTIARRHYTHMIC AGENT; CHLORAMPHENICOL; CIPROFLOXACIN; CYTOCHROME P450; ENOXACIN; ETHAMBUTOL; FLEROXACIN; GATIFLOXACIN; GEMIFLOXACIN; GREPAFLOXACIN; ISONIAZID; LEVOFLOXACIN; LOMEFLOXACIN; MOXIFLOXACIN; NORFLOXACIN; OFLOXACIN; PEFLOXACIN; PRULIFLOXACIN; PYRAZINAMIDE; QUINOLONE DERIVATIVE; RIFAMPICIN; RUFLOXACIN; SITAFLOXACIN; SOTALOL; SPARFLOXACIN; TEMAFLOXACIN; TROVAFLOXACIN;

ABDOMINAL PAIN; AMYLASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANOREXIA; ANTIBACTERIAL ACTIVITY; ANTIMICROBIAL ACTIVITY; ANXIETY; AREA UNDER THE CURVE; ARTHRALGIA; ARTHROPATHY; ASTHENIA; BACTERICIDAL ACTIVITY; CARDIOVASCULAR DISEASE; CHLAMYDOPHILA PNEUMONIAE; CONSTIPATION; DIARRHEA; DIZZINESS; DNA DRUG COMPLEX; DOG; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG SOLUBILITY; DRUG TARGETING; DRUG TOLERANCE; DRUG WITHDRAWAL; DYSPEPSIA; ENZYME INHIBITION; EOSINOPHILIA; ESCHERICHIA COLI; EYE TOXICITY; FLATULENCE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLOSSITIS; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS PARAINFLUENZAE; HEADACHE; HEART PALPITATION; HELICOBACTER PYLORI; HEMATOLOGIC DISEASE; HUMAN; HUMAN CELL; HYPOGLYCEMIA; INSOMNIA; KLEBSIELLA PNEUMONIAE; LACTATE DEHYDROGENASE BLOOD LEVEL; LD 50; LEUKOPENIA; LIVER FUNCTION TEST; LUNG TUBERCULOSIS; MALAISE; METABOLIC DISORDER; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; MOUSE; MYALGIA; MYCOBACTERIUM TUBERCULOSIS; MYCOPLASMA PNEUMONIAE; NAUSEA; NERVOUSNESS; NONHUMAN; PHLEBITIS; PLASMA HALF LIFE; PRIORITY JOURNAL; PROTHROMBIN TIME; PRURITUS; QT PROLONGATION; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; STAPHYLOCOCCUS AUREUS; STOMATITIS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; SWEATING; TACHYCARDIA; TASTE AVERSION; THROMBOCYTHEMIA; THRUSH; TORSADE DES POINTES; TREATMENT DURATION; TREMOR; TREPONEMA PALLIDUM; URINARY EXCRETION; URTICARIA; VAGINA CANDIDIASIS; VAGINITIS; VERTIGO; XEROSTOMIA;

ANIMALS; ANTITUBERCULAR AGENTS; AZA COMPOUNDS; HUMANS; QUINOLINES; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 43249087500     PISSN: 14729792     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1472-9792(08)70016-7     Document Type: Review

References (28)

1. Champoux J. DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem 70 (2001) 369-413
2. Gordon S., et al. Genomics of Mycobacterium bovis. Tuberculosis 81 1-2 (2001) 157-163
3. Aubry A., et al. First functional characterization of a singly expressed bacterial type II topoisomerase: the enzyme from Mycobacterium tuberculosis. Biochem Biophys Res Commun 348 (2006) 158-165
4. Aubry A., et al. Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes. Antimicrob Agents Chemother 50 (2006) 104-112
5. Kam K., et al. Stepwise decrease in moxifloxacin susceptibility amongst clinical isolates of multidrug-resistant Mycobacterium tuberculosis: correlation with ofloxacin susceptibility. Microb Drug Res 12 (2006) 7-11
6. Hu Y., et al. Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob Agents Chemother 47 (2003) 653-657
7. Rodriguez Diaz J., et al. In vitro activity of new fluoroquinolones and linezolid against nontuberculous mycobacteria. Int J Antimicrob Agents 21 (2003) 585-588
8. Rodríguez J., et al. In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis. Int J Antimicrob Agents 17 (2001) 229-231
9. Lu T., and Drlica K. In vitro activity of C-8-methoxy fluoroquinolones against mycobacteria when combined with anti-tuberculosis agents. J Antimicrob Chemother 52 (2003) 1025-1028
10. Alvirez-Freites E., et al. In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 46 (2002) 1022-1025
11. Gradelski E., et al. Activity of gatifloxacin and ciprofloxacin in combination with other antimicrobial agents. Int J Antimicrob Agents 17 (2001) 103-107
12. Rodríguez J., et al. Mutant prevention concentration: comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis. J Antimicrob Chemother 53 (2004) 441-444
13. Nuermberger E., et al. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med 169 (2004) 421-426
14. Rosenthal I., et al. Potent twice-weekly rifapentine-containing regimens in murine tuberculosis. Am J Respir Crit Care Med 174 (2006) 94-101
15. Yoshimatsu T., et al. Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis. Antimicrob Agents Chemother 46 (2002) 1875-1879
16. Shandil R., et al. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob Agents Chemother 51 (2007) 576-582
17. Schwartz Y., et al. Novel conjugate of moxifloxacin and carboxymethylated glucan with enhanced activity against Mycobacterium tuberculosis. Antimicrob Agents Chemother 50 (2006) 1982-1988
18. Gosling R., et al. The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med 168 (2003) 1342-1345
19. Pletz M., et al. Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study. Antimicrob Agents Chemother 48 (2004) 780-782
20. Burman W., et al. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 174 (2006) 331-338
21. Siefert H., et al. Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: tissue distribution in male rats. J Antimicrob Chemother 43 Suppl B (1999) 61-67
22. Siefert H., et al. Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in human and other mammalian species. J Antimicrob Chemother 43 Suppl B (1999) 69-76
23. von Keutz E., and Schluter G. Preclinical safety evaluation of moxifloxacin, a novel fluoroquinolone. J Antimicrob Chemother 43 (1999) 91-100
24. Chaves A., et al. Cardiovascular monkey telemetry: Sensitivity to detect QT interval prolongation. J Pharmacol Toxicol Methods 54 (2006) 150-158
25. + channel HERG. Mol Pharmacol 59 (2001) 122-126
26. Berning S. The role of fluoroquinolones in tuberculosis today. Drugs 61 (2001) 9-18
27. Falagas M., et al. Arrhythmias associated with fluoroquinolone therapy. Int J Antimicrob Agents 29 (2007) 374-379
28. Owens R., and Ambrose P. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis 41 Suppl 2 (2005) S144-S157